C12N 2310/3511
Intercalating or cleaving agent
Official title: intercalating or cleaving agent
C12N2310/3511 (Intercalating or cleaving agent) appears on 82 US grants and 87 published applications in this corpus.
Search patents in C12N- Granted patents
- 82
- Published applications
- 87
- Assignees
- 53
- Inventors
- 173
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 6 | 0 |
| 1998 | 10 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 1 |
| 2002 | 5 | 3 |
| 2003 | 1 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 5 |
| 2006 | 1 | 3 |
| 2007 | 0 | 2 |
| 2008 | 3 | 2 |
| 2009 | 1 | 5 |
| 2010 | 3 | 2 |
| 2011 | 2 | 4 |
| 2012 | 1 | 1 |
| 2013 | 1 | 1 |
| 2014 | 2 | 3 |
| 2015 | 6 | 6 |
| 2016 | 1 | 7 |
| 2017 | 2 | 0 |
| 2018 | 5 | 8 |
| 2019 | 2 | 2 |
| 2020 | 3 | 3 |
| 2021 | 3 | 6 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 0 | 6 |
| 2025 | 2 | 4 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Light-inducible CRISPR/Cas9 system for genome editing28 Apr 2026US 12,612,624 B2The Johns Hopkins University
- Compositions and methods for modulating TTR expression6 Jan 2026US 12,516,319 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating apolipoprotein C-III expression30 Dec 2025US 12,509,684 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating apolipoprotein (a) expression6 May 2025US 12,291,709 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating apolipoprotein (a) expression26 Dec 2023US 11,851,655 B2Ionis Pharmaceuticals, Inc.
- Conjugated antisense compounds and their use3 Sep 2026US 2026/0258417 A1Ionis Pharmaceuticals, Inc.
- Conjugated antisense compounds and their use27 Aug 2026US 2026/0250680 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating ttr expression13 Aug 2026US 2026/0234624 A1Ionis Pharmaceuticals, Inc.
- Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker26 Feb 2026US 2026/0055411 A1Lonza Sales AG
- Compositions and methods for modulating apolipoprotein c-iii expression5 Feb 2026US 2026/0035695 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997
- Method of expanded porphyrin-oligonucleotide conjugate synthesis325US 5,565,552 ABoard of Regents, Univ. of Texas Sys. · 1996
- Oligonucleotides having chiral phosphorus linkages234US 6,239,265 B1Isis Pharmaceuticals, Inc. · 2001
- Chromophore probe for detection of nucleic acid221US 5,595,726 ABoard of Trustees, Univ. of TX Sys. · 1997